Litigation Summary and Analysis for Pacira Pharmaceuticals, Inc. v. The WhiteOak Group, Inc. | 1:25-cv-01445
Executive Summary
This litigation concerns patent infringement allegations brought by Pacira Pharmaceuticals, Inc. against The WhiteOak Group, Inc. in the United States District Court for the District of New Jersey (docket number 1:25-cv-01445). The case centers on patent rights for long-acting bupivacaine formulations used in post-surgical pain management.
As of the latest available filings, the case involves claims of infringement by WhiteOak on patents licensed or owned by Pacira, with disputes over validity, infringement, and potential damages. The proceedings are significant for stakeholders in pharmaceutical innovation, patent law, and commercial drug supply chains.
Key Facts at a Glance
Aspect
Details
Court
U.S. District Court, District of New Jersey
Docket
1:25-cv-01445
Filing Date
Early 2025 (exact date unspecified)
Parties
Pacira Pharmaceuticals, Inc. (Plaintiff) vs. The WhiteOak Group, Inc. (Defendant)
